Treatment of Plasmacytoma in Dogs
Surgical excision with wide margins is the primary treatment for solitary plasmacytomas in dogs, followed by definitive-intent radiation therapy (48 Gy in 3 Gy fractions) for incomplete margins, recurrence, or unresectable tumors.
Staging Before Treatment
Before initiating therapy, complete staging is essential to distinguish solitary plasmacytoma from multiple myeloma:
- Bone marrow aspirate/biopsy - Rule out bone marrow involvement (>10% plasma cells indicates multiple myeloma)
- Serum protein electrophoresis - Detect monoclonal gammopathy
- Serum free light chain (SFLC) ratio - Abnormal ratio predicts higher progression risk 1
- Complete blood count and serum chemistry - Assess for hypercalcemia, anemia, renal dysfunction
- Skeletal radiographs or CT - Identify additional bone lesions
- Thoracic radiographs - Rule out metastatic disease
- Abdominal ultrasound - Evaluate for hepatic or other visceral involvement 2
Treatment Algorithm by Location and Presentation
Solitary Cutaneous/Oral Extramedullary Plasmacytoma
Primary approach: Surgical excision with 2-3 cm margins 3, 4
- Complete excision with clean margins provides median survival >900 days 4
- Critical pitfall: Rectal plasmacytomas closer to the anus have better outcomes; tumors farther from the anus and incomplete margins significantly increase recurrence risk (31.5% recurrence rate overall) 3
- Surgeon experience matters - less experienced surgeons have higher recurrence rates 3
For incomplete margins or recurrence: Definitive radiation therapy
- 48 Gy total dose in 3 Gy fractions (median protocol) 5
- Achieves complete response in 73% of cases (16/22 evaluable dogs) 5
- Median progression-free survival: 611 days 5
Solitary Osseous Plasmacytoma (Bone)
Primary approach: Definitive-intent radiation therapy 6, 5
- Most commonly affects vertebrae (8/13 cases) 6
- Recommended protocol: 48 Gy in 3 Gy fractions over 16 treatments 5
- Median survival: 1,166 days for dogs completing radiation 6
- Neoadjuvant surgery may be considered for accessible lesions (5/10 cases in one series) 6
- Median progression-free interval: 310 days 6
Important distinction: Unlike humans, canine solitary osseous plasmacytomas rarely progress to multiple myeloma (0/13 cases in the largest series) 6
Disseminated or Aggressive Disease
For suspected metastatic disease (e.g., hepatic involvement): Systemic chemotherapy 2
- Pulse-dose melphalan protocol with prednisone
- Starting dose: Melphalan 7 mg/m² PO for 5 consecutive days every 3 weeks
- Critical adjustment strategy: If dose-limiting myelosuppression occurs, shorten melphalan duration (e.g., 3-4 days instead of 5) while maintaining the 3-week cycle 2
- Monitor CBC weekly during initial cycles
- One case achieved 19+ months survival with progressive hepatic lesion regression 2
Prognostic Factors and Monitoring
High-risk features requiring closer surveillance:
- Histologic parameters: >28 mitotic figures per 10 high-power fields predicts progression 4
- Moderate-to-severe nuclear atypia associated with tumor-related death 4
- Incomplete surgical margins 3
- Abnormal SFLC ratio at diagnosis 1
- Multiple lesions on imaging 1
Follow-up protocol:
- Physical examination every 3 months for 2 years, then every 6 months
- Repeat serum protein electrophoresis every 3-6 months
- Key prognostic indicator: Persistence of monoclonal protein after treatment predicts 71% progression vs. 9% if resolved 7
- Imaging of primary site every 3-6 months for first 2 years
- Annual skeletal survey to monitor for new bone lesions
Treatment Response Expectations
Radiation therapy outcomes:
- Complete response strongly preferred over partial response - partial response associated with inferior progression-free survival and overall survival 5
- Definitive-intent protocols (42-54 Gy) superior to palliative protocols (20-35 Gy) 5
- 95% overall response rate (complete or partial) 5
Surgical outcomes:
- Rectal plasmacytomas: 1-year survival 95%, 3-year survival 66% 3
- Metastasis rate approximately 10% 3 - significantly higher than historically reported
- Oral plasmacytomas: median survival 973 days, but nearly 1/3 show disease progression 4
Critical Clinical Pitfalls
- Underestimating metastatic potential: Recent evidence shows extramedullary plasmacytomas have greater metastatic capacity than previously recognized 2, 3
- Inadequate staging: Failure to perform bone marrow evaluation and complete imaging may miss systemic disease
- Conservative surgery for rectal masses: While associated with long survival, recurrence is common (31.5%) 3
- Using palliative radiation doses: Definitive protocols provide significantly better outcomes 5